Brian Slomovitz, MD, Reviews Adjuvant Pembrolizumab and Chemo +/– Radiotherapy in Endometrial Cancer

Video

Brian Slomovitz, MD, Reviews Adjuvant Pembrolizumab and Chemo +/– Radiotherapy in Endometrial Cancer

During The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Brian Slomovitz, MD, leader of endometrial trial for the Gynecologic Oncology Group (GOG) Foundation, and a gynecologic oncologist at Mount Sinai Medical Center in Miami Beach, Florida, about the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial in progress (NCT04634877) that is in progress with schema presented at the conference. This trial isHe and his co-investigators are examining observing the use of pembrolizumab (Keytruda) or vs placebo with plus adjuvant chemotherapy, with or without radiotherapy for patients who havewith newly diagnosed, high-risk endometrial cancer.

Transcript:

I’m fortunate enough at this meeting to present a trial in progress in the adjuvant setting in women with high-risk endometrial cancer [who are receiving] chemotherapy, plus or minus pembrolizumab in the treatment of this disease. One of the things that’s nice about this trial is that we’re allowing radiation therapy as an option based on clinician discretion. Now, adjuvant trials for endometrial cancer have been very difficult to get up and running. This study is looking to enroll 990 patients into a huge global trial sponsored by Merck and being run through ENGOT [European Network of Gynecological Oncological Trial Groups] and the GOG.

The purpose of this trial is to see if we can better the outcomes in women with high-risk endometrial cancer. Now at this point, we know that immunotherapy works in women with recurrent disease; if , whether they have microsatellite instability, immunotherapy in the single-agent setting would be indicated. Now if women are microsatellite stable, or what we call proficient in MMR, mismatch repair, then those women will get the combination of pembrolizumab and lenvatinib [Lenvima]. The purpose of this trial is to see if we can go back to 2 levels, not for first line but in the adjuvant setting, to see if immunotherapy works.

Reference

Slomovitz B, Mirza MR, Lortholary A, et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: a phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed high-risk endometrial cancer. Presented at: Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer. March 18-21, 2022. Phoenix, AZ. Poster 570.

Related Videos
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Related Content